Press Releases Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-03-05 EST			5-day change	1st Jan Change
91.41 ^USD	-3.61%		+3.42%	+4.66%

03-02	Takeda and Protagonist Therapeutics, Inc Announce FDA Accepts Priority Review for First-In-Class Therapy Rusfertide in Polycythemia Vera	CI
03-02	Wedbush Raises Price Target on Protagonist Therapeutics to $100 From $86, Keeps Outperform Rating	MT

Press Releases

02-26	Protagonist Therapeutics: Q4 Earnings Snapshot	AQ
02-25	Protagonist Therapeutics : Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	PU
11-06	Protagonist Therapeutics : Reports Third Quarter 2025 Financial Results and Provides Corporate Update	PU
11-06	Protagonist Therapeutics: Q3 Earnings Snapshot	AQ
25-10-21	Big Pharma Just Put Peptides Back on the Map - Which Players Are Still Under the Radar?	AQ
25-08-06	Protagonist Therapeutics: Q2 Earnings Snapshot	AQ
25-05-06	Protagonist Therapeutics: Q1 Earnings Snapshot	AQ
25-05-05	Protagonist Therapeutics : Reports Q1 2025 Financial Results and Provides Corporate Update	PU
25-02-24	Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update	AQ
25-02-21	Protagonist Therapeutics: Q4 Earnings Snapshot	AQ
24-11-20	Protagonist Therapeutics to Host Conference Call to Announce an Oral Peptide IL-17 Antagonist Development Candidate	AQ
24-11-18	Protagonist Therapeutics : announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ 2113) in plaque psoriasis, a first in class investigational targeted oral peptide that selectively blocks the IL 23 receptor Form 8 K	PU
24-11-07	Protagonist Therapeutics : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
24-11-07	Protagonist Therapeutics : Reports Third Quarter 2024 Financial Results and Provides Corporate Update Form 8 K	PU
24-11-07	Protagonist Therapeutics: Q3 Earnings Snapshot	AQ
24-09-04	Protagonist Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference 2024	AQ
24-08-07	Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update	AQ
24-08-06	Protagonist Therapeutics: Q2 Earnings Snapshot	AQ
24-08-02	Protagonist Therapeutics - RETRANSMISSION, Preclinical and Clinical Pharmacokinetic, Pharmacodynamic, and Safety Data of Targeted Oral Peptide JNJ-2113 Published in Scientific Reports	AQ
24-08-01	Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor	AQ
24-07-23	Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024	AQ
24-06-28	Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024	AQ
24-06-17	Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control	AQ
24-05-07	Protagonist Therapeutics: Q1 Earnings Snapshot	AQ
24-03-27	Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data	AQ